Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program
— CYB003 is the first psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder — May 31, 2022 08:00 AM Eastern Daylight Time TORONTO — Cybin Inc. (NEO:CYBN)(NYSE:CYBN)(Cybin ... [Read]